
SBBP
Healthcare · Biotechnology · $135.7M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2021
EPS trend, 90 days to now · +11.1% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 5, 2021 | After the close | -0.10 | -0.07 | +28.2% |
| May 12, 2021 | After the close | -0.10 | -0.11 | -10.0% |
| Mar 3, 2021 | After the close | -0.11 | -0.11 | +2.9% |
| Oct 29, 2020 | After the close | -0.13 | -0.12 | +5.3% |
| Aug 4, 2020 | After the close | -0.20 | -0.12 | +40.0% |
| May 6, 2020 | After the close | -0.23 | -0.19 | +18.1% |
| Feb 25, 2020 | After the close | -0.27 | -0.25 | +5.7% |
| Nov 7, 2019 | After the close | -0.28 | -0.25 | +9.1% |
| Jul 31, 2019 | After the close | -0.27 | -0.24 | +10.4% |
| May 1, 2019 | After the close | -0.33 | -0.25 | +24.8% |
| Feb 26, 2019 | After the close | -0.51 | -0.46 | +9.4% |
| Oct 31, 2018 | After the close | -0.45 | -0.47 | -4.4% |
| Aug 8, 2018 | Before the open | -0.47 | -0.36 |
As of October 5, 2021, Strongbridge Biopharma plc was acquired by Xeris Pharmaceuticals, Inc. Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of…
| +24.2% |
| May 10, 2018 | After the close | -0.39 | -0.33 | +15.9% |
| Mar 12, 2018 | After the close | -0.32 | -0.31 | +3.7% |